This author has yet to write their bio.
Meanwhile lets just say that we are proud admin contributed a whooping 52 entries.
· MANUFACTURING As part of Eisai’s global manufacturing system, Eisai Suzhou factory carries out all manufacturing processes from local production of tablets, capsules and injections to the repackaging of the imported semi-products. The factory sits on a sprawling land of 25,000m2?in Suzhou Industrial Park and is equipped with state-of-the-art machineries. In 2004, the total investment […]
In line with Eisai’s General Policy on Product Quality (i.e.?“The quality of every single tablet, capsule and ampoule that we produce is integral to the life of the patient”), Eisai China, Inc. is committed to ensuring that only high quality products come out of its Suzhou factory. To this end, all manufacturing operations in the […]
· Environmental Protection In line with Eisai’s?Environmental Protection Policy, Eisai China Inc. is making every effort to protect the environment and continuously implements cleaner, energy saving production processes at its Suzhou plant. To decrease energy consumption, we have installed high-efficient illumination system, energy-saving lamps and other energy-saving equipment in the plant. Taking advantage of advanced […]
?Eisai China Headquarter Address: Floor 39-40, Park Place, No. 1601, Nanjing West Road, Jing’an District, Shanghai Tel: 86-21-2419-2888 Fax: 86-21-2419-2891 Postal code: 200040 Website：www.9-design.net ?Eisai China Holdings Ltd. Eisai China Inc. Registered Address: No.168, Xingpu Road, Suzhou Industrial Park, Suzhou Tel: 86-512-69566776 Fax: 86-512-67618640? Postal code: 215021 ?Eisai (Liaoning) Pharmaceutical Co., Ltd. […]
It has been 32 years since Eisai came to China in 1991. It is fair to say that Eisai’s relationship with China is long-standing and well-established. Prof. Hans Mueller, Vice President of Beijing Medical College (now Peking University Health Science Center) and his wife together with their team visited Kawashima Plant in 1972 when China […]
Eisai’s affiliates in China are wholly-owned by Eisai Co., Ltd., a Japanese multinational pharmaceutical company headquartered in Tokyo, with strong R&D capabilities. It was founded in1941. Since its foundation, the company has actively expanded into overseas markets and now has sales subsidiaries and factories in America, Europe and Asia. Eisai China has been smoothly developing […]
If approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimer’s disease
Aducanumab is now under regulatory review in Japan, Europe and the United States
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa?), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.
This collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of α-synuclein misfolding and aggregation
AbbVie GK (Headquarters: Minato-ku, Tokyo; President: James Feliciano, hereafter “AbbVie”) and Eisai Co., Ltd. (Headquarters: Tokyo; CEO: Haruo Naito, hereafter “Eisai”) today announced an approval of additional indication of HUMIRA??(generic name: adalimumab [recombinant], hereafter “HUMIRA”), a fully human anti-TNFα monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter “PG”). HUMIRA was granted orphan drug designation for the treatment of PG in 2019. This indication counts for HUMIRA’s 12th indication in Japan and makes HUMIRA the world’s first drug indicated for the treatment of PG.
Copyright(c) 2011 Eisai China lnc.All Rights Reserved.
滬ICP備11005394號-1
滬公網安備31010602001439號
021-62881220
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy